Johnson & Johnson Q3 2026 Earnings: $0.09 EPS on $25.4B Sales as a $5.5B Talc Charge Meets a Guidance Raise

On October 13, 2026, Johnson & Johnson reported third-quarter sales of $25,399 million, up 5.9% year over year, and net earnings of $210 million — down 95.9%, worth $0.09 of diluted EPS. The two numbers describe the same quarter honestly: an operating business growing 6% underneath approximately $7 billion of one-time charges, led by a $5.5 billion proposed resolution of the ovarian talc litigation plus the Firefly Bio acquisition and Sail Biomedicines collaboration. Management then raised full-year guidance to $101.2 billion of sales and $11.10 of adjusted EPS at the midpoints. This is the quarter J&J paid for its past and priced in its future on the same income statement.

The Headline Numbers​

J&J's fiscal quarters end on Sundays; Q3 2026 is the thirteen weeks ended September 27, 2026. Every figure below comes from the Form 10-Q filed October 21, cross-checked line by line against the Form 8-K earnings release and its financial schedules with the earnings call presentation.

The anatomy of the $0.09 is fully disclosed, and investor-relations head Ryan Koors put the total on the call: results "were impacted by the proposed talc litigation resolution as well as expenses associated with the Firefly Bio transaction and Sail Biomedicines' collaboration amounting to approximately $7 billion." The reconciliation schedule itemizes it: $5,519 million of litigation charges (the proposed $5.5 billion ovarian talc resolution), roughly $1 billion of acquired in-process R&D inside the R&D line for Firefly Bio (an asset acquisition, expensed immediately), $369 million of Orthopaedics separation costs, $339 million of IPR&D impairments (the preCARDIA write-off, a non-core asset inherited with Abiomed), and $1,240 million of intangible amortization. Earnings before tax of $34 million on $25.4 billion of sales is not a business running at zero margin — it is a $7.7 billion adjusted pre-tax quarter with $7.6 billion of charges stacked on top.

Two subtleties matter. First, the tax line flipped to a $176 million benefit (a (517.6)% effective rate) "primarily related to the positive tax effect associated with the accrual for the proposed talc litigation resolution" — the charge buys its own tax shield in the same quarter. Second, adjusted EPS of $2.59 includes the Firefly and Sail deal costs: they dilute adjusted EPS by about $0.64 this year, so the "clean" growth rate CFO Joseph Wolk quoted is roughly 9%, not the reported -7.5%. The deals will dilute 2027 adjusted EPS by a combined $1.36 — a number to carry into every 2027 model.

Revenue Deep Dive​

The thesis the segment mix supports is that J&J is now a pharmaceutical growth company with a medical-device stabilizer attached: Innovative Medicine grew nearly 8% while absorbing a biosimilar cliff, and MedTech grew 2.5% while missing its own expectations.

Innovative Medicine (+7.9% operational) is the quarter's triumph, and the release quantifies exactly what it overcame: STELARA's biosimilar-driven 54% decline was "an approximate 690 basis points impact" — without it, the segment grew roughly 15%. Growth came from three engines. In Oncology (+16.4%), DARZALEX grew 15.6% on five points of share gains, CARVYKTI 35.2% on earlier-line adoption and site expansion, TECVAYLI 77.3% (over 100% in the US after the DARZALEX FASPRO combination approval), and RYBREVANT plus LAZCLUZE 63.5% on launch uptake. In Immunology (+1.3%), TREMFYA's 68.2% surge — four points of share in both ulcerative colitis and Crohn's — nearly covered the STELARA hole by itself, with management calling TREMFYA "the fastest growing biologic across all indications" for new IBD patient starts. In Neuroscience (+17.3%), SPRAVATO grew 36% and CAPLYTA 66.1%, crossing $1 billion year-to-date to become J&J's 29th billion-dollar platform. The new-launch theme management claims is specific and checkable: "Strong operational growth of 7.9% driven primarily by new product launches," with ICOTYDE "off to an incredibly great start," "tracking better than some of most all launches in psoriatic diseases" (20,000 patients, ~9,000 prescribers, 60% systemic-naive — "expanding the systemic marketplace") and INLEXZO "rapidly emerged as a market leader" one year post-launch with Q3 sales north of $90 million.

MedTech (+2.5%) is the quarter's acknowledged miss. CEO Joaquin Duato said it "fell short of our expectations," and MedTech chief Tim Schmid was blunter: "our performance is below the standard we have set internally." The geography tells the story: the US grew a "robust" 4.8% while international managed 0.1%, weighed down by China volume-based procurement, the surgery transformation program, and "incremental pressure" from Middle East disruptions to tender timing. Inside the franchises, electrophysiology grew 4.4% (VARIPULSE passed 100,000 treated AFib patients; VARIPULSE Pro is driving double-digit growth in Europe), Shockwave grew 17.2%, and contact lenses rode "strategic price actions" — one of the only pricing-momentum phrases in the entire quarter. The offsets: Abiomed declined 1.5% on lower patient volumes tied to an out-of-US high-risk PCI study management disputes ("we actually believe that the methodology employed did not follow well established practices"), and Surgery fell 1%. The demand signals that do appear are franchise-specific — "robust demand for premium IOLs," "increased patient demand" for SPRAVATO — while classic shortage language (supply constraints, sold-out capacity) is entirely absent. This is a demand-soft-in-spots quarter, not a supply-constrained one.

The Margin Story​

Gross margin fell 1.5 points to 68.1%, and Koors gave the mechanical walk: cost of goods "deleveraged by 150 basis points, driven by unfavorable product sales mix and increased intangible asset amortization expense in the Innovative Medicine segment for Intra-Cellular, partially offset by the impact of tariff recoveries in the MedTech business." Below gross profit, SM&A held exactly flat at 24.7% of sales — "consistent commercial investments" scaling perfectly with revenue — while R&D jumped three points to 18.3% because the $1 billion Firefly charge lands there. The segment margins show where the deals bit: Innovative Medicine adjusted income before tax fell from 44.3% to 35.4% of sales on the Firefly IPR&D, Sail transaction costs and mix, while MedTech's rose from 21.0% to 22.9% on tariff recoveries. For the full year, Wolk now expects operating margin down only about 60 basis points (improved from 75), with the deals costing 150 — "absent those deals, we continue to deliver base margin improvement." The margin story, in short, is a clean operating print wearing a deal costume.

The One Big Question: Is $0.09 the Bottom of the Talc Era?​

Every J&J quarter for a decade has really been two stories — the healthcare business and the talc docket — and this is the quarter the docket finally got a price tag: a $5.5 billion proposed resolution of the remaining ovarian talc litigation, conditioned on at least 95% participation of the remaining claimants ("we are trending to meet the 95% threshold," per Wolk), with the first payment of up to $3 billion due in 2027. The GAAP-to-adjusted bridge below is the quarter in miniature:

The bridge answers the question two ways. The talc line ($5,519 million) is 90% of the gap between reported and adjusted earnings — genuinely the quarter. But the remaining $1 billion-plus of "special" charges (Ortho separation, restructuring, amortization) recurs every quarter in some form, which is why adjusted EPS still fell 7.5%: the Firefly and Sail costs sit inside the adjusted number by design. So $0.09 is almost certainly the GAAP bottom of this litigation cycle — a single accrual that will not repeat — while the adjusted trajectory still has to digest $1.36 of 2027 deal dilution before the double-digit growth management promises "by the end of the decade." The second separation sharpens the stakes: DePuy Synthes (Orthopaedics) is "on track" for separation by mid-2027, with management "leaning towards a spin" — a second Kenvue-style unlock that would leave J&J a pure Innovative Medicine plus high-growth MedTech company, and whose $369 million quarterly separation bill is already running through the P&L.

Tracking a $25.4B Quarter in Plain Text​

Double-entry forces every dollar to reconcile, which is why the Beancount ledger is the audit — and how we model every company explains the conventions this file follows. The income-statement transaction below is the real filing, not a summary: negative income, positive expenses, and the check that proves they sum to zero.

; Check: -25399 + 8097 + 6285 + 4652 + 339 - 186 + 217 + 5519 + 261 + 181 - 176 + 210 = 0 ✓
 
2026-09-27 * "Johnson & Johnson" "FY2026Q3 Income Statement"
  Income:Revenue                         -25399 MUSD  ; sales to customers (Innovative Medicine 16,757 + MedTech 8,642)
  Expenses:CostOfRevenue                   8097 MUSD  ; cost of products sold (incl. ~$0.2B MedTech tariff recoveries, 10-Q MD&A)
  Expenses:SellingGeneralAdministrative     6285 MUSD  ; selling, marketing and administrative expenses
  Expenses:ResearchAndDevelopment          4652 MUSD  ; research and development expense (incl. ~$1.0B Firefly Bio acquired IPR&D and $0.3B Sail Biomedicines option premium, 10-Q MD&A)
  Expenses:OtherNet                          339 MUSD  ; in-process research and development impairments
  Expenses:OtherNet                         -186 MUSD  ; interest income
  Expenses:OtherNet                          217 MUSD  ; interest expense, net of portion capitalized
  Expenses:OtherNet                         5519 MUSD  ; litigation charges per the 8-K (Ex. 99.1) reconciliation, incl. the proposed $5.5B ovarian talc resolution (10-Q Note 11)
  Expenses:OtherNet                          261 MUSD  ; other (income) expense residual (5,780 filed line less 5,519 litigation)
  Expenses:OtherNet                          181 MUSD  ; restructuring
  Expenses:IncomeTax                        -176 MUSD  ; (benefit from) provision for taxes on income — tax shield on the talc accrual
  Equity:Adjustments                         210 MUSD  ; net earnings offset

That block is not an illustration; it is the period that was validated and pushed to open_ledger/johnson-johnson, cross-checked three ways: the Form 10-Q, the release's schedules, and the earnings presentation. The one balance-sheet number that tells the narrative is treasury stock of $76.2 billion — nearly matching the entire $81.5 billion of shareholders' equity. It got there in a single year: the August 2023 Kenvue exchange offer retired J&J shares for Kenvue shares, taking treasury stock from $41.7 billion to $75.7 billion in FY2023. The balance sheet still carries the receipt for the last separation — at roughly $17 billion of cash and marketable securities against $45 billion of debt (per the 10-Q balance sheet), with the first $3 billion talc payment due in 2027 and a DePuy Synthes spin on track for mid-2027, it is about to carry two more.

The Multi-Year Arc​

*Includes $21,827M of discontinued operations, chiefly the $20,984M gain on the Kenvue separation.

Revenue in the ledger is continuing operations only — Innovative Medicine plus MedTech — which is why the arc reads clean while net income lurches: FY2023's 41.3% margin is the Kenvue gain, and Q3's 0.8% is the talc accrual, and neither tells you about the underlying business. The underlying business is the revenue column: $78.7 billion → $94.2 billion in four years, a 19.6% climb with a visible acceleration (FY2025 grew 6.0%, and 2026 is guided to 7.4% reported at the midpoint — the first $100 billion year in the company's 140-year history). The segment split underneath shows the quality of that growth: Innovative Medicine went $51.7 billion → $60.4 billion while MedTech went $27.1 billion → $33.8 billion, and both grew through FY2026's third quarter despite STELARA's 690-basis-point biosimilar drag — "we proved our ability to grow through a significant loss of exclusivity," as Duato put it. R&D ran $14–17 billion a year across the arc (15–19% of sales), the price of a pipeline that now has to replace STELARA with TREMFYA, ICOTYDE and the multiple-myeloma franchise. The compounding story is a pharmaceutical company outgrowing its patent cliffs while its device business compounds quietly — until this quarter, when the past (talc) and the future (Firefly, Sail, OTTAVA, the Ortho spin) both sent invoices at once.

The Verdict: Bull vs. Bear​

Bull Case

• The operating business accelerated: 6.0% operational sales growth, "ahead of analyst consensus" and quicker sequentially, with eight Innovative Medicine brands growing double-digits and the full-year guide raised on both sales ($101.2 billion) and adjusted EPS ($11.10).
• STELARA's 690-basis-point drag is being outgrown in real time: TREMFYA +68.2%, DARZALEX +15.6%, CARVYKTI +35.2%, SPRAVATO +36% and CAPLYTA +66.1% more than covered a 54% STELARA collapse — the loss-of-exclusivity playbook is working.
• The launch wave is measurable, not promised: ICOTYDE is "tracking better than some of most all launches in psoriatic diseases" with 60% of patients new to systemic therapy, INLEXZO topped $90 million in Q3 toward a $5 billion-plus platform, and OTTAVA's De Novo authorization opens surgical robotics with a first customer signed.
• The talc number is now capped and scheduled: $5.5 billion at 95% participation, first payment in 2027 — converting a decade-long open liability into a financeable outflow, with its own $1.7 billion quarterly tax shield.
• A second separation unlock is forming: DePuy Synthes is on track for mid-2027 with management leaning toward a spin, repeating the Kenvue playbook that retired $34 billion of J&J shares last time.

Bear Case

• Adjusted EPS fell 7.5% on 5.9% sales growth — negative operating leverage after deals, with Innovative Medicine's adjusted margin collapsing nine points (44.3% → 35.4%) and $1.36 of combined Firefly/Sail dilution waiting in 2027.
• MedTech missed its own bar two ways: 2.5% growth "below the standard we have set internally," with international sales flat (+0.1%), Abiomed declining on a disputed study, and China VBP plus Middle East disruption as structural-looking headwinds.
• The $5.5 billion needs 95% of claimants to say yes; anything short reopens the docket, and the payment schedule ($3 billion in 2027) lands in the same year as peak deal dilution.
• Gross margin keeps leaking: 69.6% → 68.1% on unfavorable mix plus Intra-Cellular amortization, and tariff recoveries (this quarter's offset) are one-time by nature.
• The double-digit-growth-by-decade's-end promise assumes no M&A while requiring the pipeline (ICOTYDE indications, milvexian Factor XI data, OTTAVA ramp, INLEXZO label expansion) to hit on nearly every cylinder.

Our Take

Buy the business, rent the litigation outcome. The 6% operational growth through a biosimilar cliff, the raised guide, and a launch cohort with real patient counts are the marks of a pharmaceutical company executing at a high level — and $0.09 of GAAP EPS is the price of closing the books on talc, not a verdict on the franchise. But the quarter's honesty cuts both ways: management told you adjusted earnings fell, MedTech missed, and 2027 carries $1.36 of deal dilution before any growth shows. The number to watch is not sales but Innovative Medicine's adjusted margin over the next two quarters: if it rebuilds toward 40% as the Firefly charge laps, this was a one-quarter kitchen sink on the way to $100 billion-plus; if it sticks in the mid-30s, the deals bought growth at the cost of the P&L. Either way, the ledger will show it first.